Citations

Showing 10 of 108162 citations.

Clinical Diagnostic Testing for Human Cytomegalovirus Infections
Inoue, Naoki , Pinninti, Swetha , Boppana, Suresh B. , Simonazzi, Giuliana , Pellett, Philip E. , Schmid, D. Scott , Razonable, Raymund R. , Lazzarotto, Tiziana , Gabrielli, Liliana

Mayo Clinic

The Journal of Infectious Diseases | November 22, 2019 | Volume: 221 | Issue: Supplement_1 | Pages: S74-S85

10.1093/infdis/jiz601 | PMID 32134488 Get It

Abstract Human cytomegalovirus (HCMV) infections are among the most common complications arising in transplant patients, elevating the risk of various complications including loss of graft and death. HCMV infections are also responsible for more congenital infections worldwide than any other agent. Congenital HCMV (cCMV) infections are the leading nongenetic cause of sensorineural hearing loss and a source of significant neurological disabilities in children. While there is overlap in the clinical and laboratory approaches to diagnosis of HCMV infections in these settings, the management, follow-up, treatment, and diagnostic strategies differ considerably. As yet, no country has implemented a universal screening program for cCMV. Here, we summarize the issues, limitations, and application of diagnostic strategies for transplant recipients and congenital infection, including examples of screening programs for congenital HCMV that have been implemented at several centers in Japan, Italy, and the United States.
Clinical Validation of a Ray-Casting Analytical Dose Engine for Spot Scanning Proton Delivery Systems
Younkin, James E. , Morales, Danairis Hernandez, Shen, Jiajian , Shan, Jie , Lentz, Jarrod M. , Stoker, Joshua B., Ding, Xiaoning, Bues, Martin , Schild, Steven E. , Shen, Jiajian , Liu, Wei

Mayo Clinic

Technology in Cancer Research & Treatment | November 22, 2019 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/1533033819887182 | PMID 31755362 Get It

Purpose: To describe and validate the dose calculation algorithm of an independent second-dose check software for spot scanning proton delivery systems with full width at half maximum between 5 and 14 mm and with a negligible spray component. Methods: The analytical dose engine of our independent second-dose check software employs an altered pencil beam algorithm with 3 lateral Gaussian components. It was commissioned using Geant4 and validated by comparison to point dose measurements at several depths within spread-out Bragg peaks of varying ranges, modulations, and field sizes. Water equivalent distance was used to compensate for inhomogeneous geometry. Twelve patients representing different disease sites were selected for validation. Dose calculation results in water were compared to a fast Monte Carlo code and ionization chamber array measurements using dose planes and dose profiles as well as 2-dimensional–3-dimensional and 3-dimensional–3-dimensional γ-index analysis. Results in patient geometry were compared to Monte Carlo simulation using dose–volume histogram indices, 3-dimensional–3-dimensional γ-index analysis, and inpatient dose profiles. Results: Dose engine model parameters were tuned to achieve 1.5% agreement with measured point doses. The in-water γ-index passing rates for the 12 patients using 3%/2 mm criteria were 99.5% ± 0.5% compared to Monte Carlo. The average inpatient γ-index analysis passing rate compared to Monte Carlo was 95.8% ± 2.9%. The average difference in mean dose to the clinical target volume between the dose engine and Monte Carlo was −0.4% ± 1.0%. For a typical plan, dose calculation time was 2 minutes on an inexpensive workstation. Conclusions: Following our commissioning process, the analytical dose engine was validated for all treatment sites except for the lung or for calculating dose–volume histogram indices involving point doses or critical structures immediately distal to target volumes. Monte Carlo simulations are recommended for these scenarios.
The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort
Digre, Kathleen B. , Tepper, Stewart J. , Spare, Nicole , Birlea, Marius , Burish, Mark J. , Mechtler, Laszlo , Gottschalk, Christopher , Quinn, Anna , Mcgillicuddy, Linda, Bance, Lisa, Dumkrieger, Gina , Schwedt, Todd J. , Dumkrieger, Gina , Ailani, Jessica , Chong, Catherine D. , Dodick, David W.

Mayo Clinic

Headache: The Journal of Head and Face Pain | November 22, 2019 | Volume: 60 | Issue: 2 | Pages: 337-347

10.1111/head.13688 | PMID 31755111 Get It

Background The American Registry for Migraine Research (ARMR) is a multicenter, prospective, longitudinal patient registry, biorepository, and neuroimaging repository that collects clinical data, electronic health record (EHR) data, blood samples, and brain imaging data from individuals with migraine or other headache types. In this manuscript, we outline ARMR research methods and report baseline data describing an initial cohort of ARMR participants. Methods Adults with any International Classification of Headache Disorders (ICHD) diagnosis were prospectively enrolled from one of the 8 participating headache specialty centers. At baseline, ARMR participants complete web‐based questionnaires, clinicians enter the participant’s ICHD diagnoses, an optional blood specimen is collected, and neuroimaging data are uploaded to the ARMR neuroimaging repository. Participants maintain the ARMR daily headache diary longitudinally and follow‐up questionnaires are completed by participants every 3 months. EHR data are integrated into the ARMR database from a subset of ARMR sites. Herein, we describe the ARMR methodology and report the summary data from ARMR participants who had, from February 2016 to May 2019, completed at least 1 baseline questionnaire from which data are reported in this manuscript. Descriptive statistics are used to provide an overview of patient’s sociodemographics, headache diagnoses, headache characteristics, most bothersome symptoms other than headache, headache‐related disability, comorbidities, and treatments. Results Data were available from 996 ARMR participants, enrolled from Mayo Clinic Arizona, Dartmouth‐Hitchcock Medical Center, University of Utah, University of Colorado, Thomas Jefferson University, University of Texas Health Science Center at Houston, Georgetown University Medical Center, and DENT Neurological Institute. Among ARMR participants, 86.7% (n = 864) were female and the mean age at the time of enrollment was 48.6 years (±13.9; range 18‐84). The most common provider‐reported diagnosis was chronic migraine (n = 622), followed by migraine without aura (n = 327), migraine with aura (n = 196), and medication overuse headache (n = 65). Average headache frequency was 19.1 ± 9.2 days per month (n = 751), with 68% reporting at least 15 headache days per month. Sensitivity to light was the most frequent (n = 222) most bothersome symptom overall, other than headache, but when present, cognitive dysfunction was most frequently (n = 157) the most bothersome symptom other than headache. Average migraine disability assessment (MIDAS) score was 52 ± 49 (n = 760), (very severe headache‐related disability); however, 17% of the ARMR population had MIDAS scores suggesting “no” or “mild” disability. The most common non‐headache health issues were allergies (n = 364), back pain (n = 296), neck pain (n = 296), depression (n = 292), and anxiety (n = 278). Nearly 85% (n = 695) of patients were using preventive medications and 24.7% were using non‐medication preventive therapy (eg, vitamins and neuromodulation). The most common preventive medication classes were neurotoxins, anticonvulsants, antidepressants, vitamins/supplements, and anticalcitonin gene‐related peptide ligand or receptor‐targeted monoclonal antibodies. Nearly 90% (n = 734) of ARMR participants was taking medications to treat migraine attacks, with the most common classes being triptans, non‐steroidal anti‐inflammatory drugs, antiemetics, acetaminophen, and combination analgesics. Conclusions ARMR is a source of real‐world patient data, biospecimens, and brain neuroimaging data that provides comprehensive insight into patients with migraine and other headache types being seen in headache specialty clinics in the United States. ARMR data will allow for longitudinal and advanced analytics that are expected to lead to a better characterization of patient heterogeneity, healthcare resource utilization, identification of endophenotypes, factors that predict treatment outcomes and clinical course, and ultimately advance the field toward precision headache medicine.
Vedolizumab quantitation using high-resolution accurate mass-mass spectrometry middle-up protein subunit: method validation
Cradic, Kendall W, Ladwig, Paula M. , Rivard, Ann L., Katrangi, Waddah, Wintgens, Karl Florian, Willrich, Maria A V, Rivard, Ann L, Willrich, Maria Alice V.

Mayo Clinic

Clinical Chemistry and Laboratory Medicine (CCLM) | November 22, 2019 | Volume: 58 | Issue: 6 | Pages: 864-872

10.1515/cclm-2019-0862 | PMID 31756160 Get It

Abstract Background While quantitation methods for small-molecule and tryptic peptide bottom-up mass spectrometry (MS) have been well defined, quantitation methods for top-down or middle-up MS approaches have not been as well defined. Therapeutic monoclonal antibodies (t-mAbs) are a group of proteins that can be used to both demonstrate the advantages of top-down or middle-up detection methods over classic tryptic peptide bottom-up along with the growing need for robust quantitation strategies/software for these top-down or middle-up methods. Bottom-up proteolytic digest methods for the t-mAbs tend to suffer from challenges such as limited peptide selection due to potential interference from the polyclonal immunoglobulin background, complicated workflows, and inadequate sensitivity and specificity without laborious purification steps, and therefore have prompted the search for new detection and quantitation methods. Time-of-flight along with Orbitrap MS have recently evolved from the research and/or pharmaceutical setting into the clinical laboratory. With their superior mass measurement accuracy, resolution and scanning speeds, these are ideal platforms for top-down or middle-up characterization and quantitation. Methods We demonstrate a validated, robust, middle-up protein subunit detection and quantitation method for the IgG1 t-mAb, vedolizumab (VEDO), which takes advantage of the high resolution of the Orbitrap MS detection and quantitation software to increase specificity. Results Validated performance characteristics met pre-defined acceptance criteria with simple workflows and rapid turnaround times: characteristics necessary for implementation into a high-volume clinical MS laboratory. Conclusions While the extraction method can easily be used with other IgG1 t-mAbs, the detection and quantitation method may become an option for measurement of other proteins.
Why We DESIRE to Directly Image Brain Myelin Using MRI
Port, John D. , Port, John D

Mayo Clinic

Radiology | November 21, 2019 | Volume: 294 | Issue: 2 | Pages: 375-376

10.1148/radiol.2019192327 | PMID 31747346 Get It

Feedback and Strategies From People With Intellectual Disability Completing a Personalized Online Weight Loss Intervention: A Qualitative Analysis
Guerra, Nichole, Neumeier, William H. , Breslin, Lauren , Geer, Betty, Ervin, David A. , Thirumalai, Mohanraj, Rimmer, James H, Thirumalai, Mohanraj , Rimmer, James Howard

Mayo Clinic

Intellectual and Developmental Disabilities | November 21, 2019 | Volume: 57 | Issue: 6 | Pages: 527-544

10.1352/1934-9556-57.6.527 | PMID 31751170 Get It

Salivary antimicrobial proteins and stress biomarkers are elevated during a 6-month mission to the International Space Station
Agha, Nadia H. , Baker, Forrest L. , Kunz, Hawley , Spielmann, Guillaume , Mylabathula, Preetesh L. , Rooney, Bridgette V. , Mehta, Satish , Pierson, Duane L., Markofski, Melissa M. , Crucian, Brian, Simpson, Richard J. , Kunz, Hawley E., Markofski, Melissa M , Simpson, Richard J , Kunz, Hawley E , Laughlin, Mitzi S.

Mayo Clinic

Journal of Applied Physiology | November 21, 2019 | Volume: 128 | Issue: 2 | Pages: 264-275

10.1152/japplphysiol.00560.2019 | PMID 31751178 Get It

As the international space community plans for manned missions to Mars, spaceflight-associated immune dysregulation has been identified as a potential risk to the health and safety of the flight crew. There is a need to determine whether salivary antimicrobial proteins, which act as a first line of innate immune defense against multiple pathogens, are altered in response to long-duration (>6 mo) missions. We collected 7 consecutive days of whole and sublingual saliva samples from eight International Space Station (ISS) crewmembers and seven ground-based control subjects at nine mission time points, ~180 and ~60 days before launch (L−180/L−60), on orbit at flight days ~10 and ~90 (FD10/FD90) and ~1 day before return (R−1), and at R+0, R+18, R+33, and R+66 days after returning to Earth. We found that salivary secretory (s)IgA, lysozyme, LL-37, and the cortisol-to-dehydroepiandrosterone ratio were elevated in the ISS crew before (L−180) and during (FD10/FD90) the mission. “Rookie” crewmembers embarking on their first spaceflight mission had lower levels of salivary sIgA but increased levels of α-amylase, lysozyme, and LL-37 during and after the mission compared with the “veteran” crew who had previously flown. Latent herpesvirus reactivation was distinct to the ~6-mo mission crewmembers who performed extravehicular activity (“spacewalks”). Crewmembers who shed at least one latent virus had higher cortisol levels than those who did not shed. We conclude that long-duration spaceflight alters the concentration and/or secretion of several antimicrobial proteins in saliva, some of which are related to crewmember flight experience, biomarkers of stress, and latent viral reactivation. NEW & NOTEWORTHY Spaceflight-associated immune dysregulation may jeopardize future exploration-class missions. Salivary antimicrobial proteins act as a first line of innate immune defense. We report here that several of these proteins are elevated in astronauts during an International Space Station mission, particularly in those embarking on their first space voyage. Astronauts who shed a latent herpesvirus also had higher concentrations of salivary cortisol compared with those who did not shed. Stress-relieving countermeasures are needed to preserve immunity and prevent viral reactivation during prolonged voyages into deep space.
Aberrant Accumulation of BRCA1 in Alzheimer Disease and Other Tauopathies
Nakamura, Masataka , Kaneko, Satoshi , Kusaka, Hirofumi , Dickson, Dennis W.

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | November 21, 2019 | Volume: 79 | Issue: 1 | Pages: 22-33

10.1093/jnen/nlz107 | PMID 31750914 Get It

Abstract BRCA1 plays an important roles in several biological events during the DNA damage response (DDR). Recently, some reports have indicated that BRCA1 dysfunction is involved in the pathogenesis of Alzheimer disease (AD). Furthermore, it has also been reported that BRCA1 accumulates within neurofibrillary tangles (NFTs) in the AD brain. In this study, we examined the immunohistochemical distribution of BRCA1 and another DDR protein, p53-Binding Protein 1 (53BP1), in AD, Pick disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration, and frontotemporal dementia with parkinsonism linked to chromosome 17. In control subjects, neither BRCA1 nor phosphorylated BRCA1 (pBRCA1; Ser1524) immunoreactivity was observed in neurons or glial cells; and that for pBRCA1 (Ser1423) and 53BP1 were slightly detected in neuronal nuclei. The immunoreactivity for both BRCA1 and pBRCA1 (Ser1423) was localized within phosphorylated tau inclusions in all tauopathies, whereas that for pBRCA1 (Ser1524) was mainly associated with Pick bodies in PiD and to a lesser extent with NFTs in AD. On the other hand, 53BP1-immunoreactive deposits tended to be increased in the nucleus of neurons in AD and PSP compared with those in control cases. Our results suggest that DDR dysfunction due to cytoplasmic sequestration of BRCA1 could be involved in the pathogenesis of tauopathies.
Conduction system pacing: Magic or Voodoo?
Yasin, Omar , Abdullah, Hafez A., Asirvatham, Samuel J. , Yasin, Omar Z, Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | November 21, 2019 | Volume: 31 | Issue: 1 | Pages: 243-246

10.1111/jce.14266 | PMID 31750589 Get It

The impact of sample processing on inflammatory markers in serum: Lessons learned
Pan, Alexander , Ryu, Euijung , Geske, Jennifer R. , Zhou, Xinyang , McElroy, Susan L. , Cicek, Mine S., Frye, Mark A. , Andreazza, Ana C. , Zhou, Xinyang Y , Andreazza, Ana C , McElroy, Susan L , Geske, Jennifer , Pan, Alexander Y., Biernacka, Joanna M.

Mayo Clinic

The World Journal of Biological Psychiatry | November 21, 2019 | Volume: 21 | Issue: 3 | Pages: 230-237

10.1080/15622975.2019.1696474 | PMID 31749403 Get It